Tenof Caution For Usage

Information for Patients: Inform patients that TENOFOVIR DISOPROXIL FUMARATE is not a cure for HIV-1 infection and patients may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. Patients should remain under the care of a physician when using tenofovir disoproxil fumarate.
Advise patients to avoid doing things that can spread HIV or HBV to others.
Do not share needles or other injection equipment.
Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.
Do not have any kind of sex without protection. Always practice safer sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.
Do not breastfeed. Tenofovir is excreted in breast milk and it is not known whether it can harm the baby. Mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.
Inform patients that: The long term effects of TENOFOVIR DISOPROXIL FUMARATE are unknown.
TENOFOVIR DISOPROXIL FUMARATE tablets are for oral ingestion only.
TENOFOVIR DISOPROXIL FUMARATE should not be discontinued without first informing their physician.
If the patient has HIV-1 infection, with or without HBV coinfection, it is important to take TENOFOVIR DISOPROXIL FUMARATE with combination therapy.
It is important to take TENOFOVIR DISOPROXIL FUMARATE on a regular dosing schedule and to avoid missing doses.
Severe acute exacerbations of hepatitis have been reported in patients who are infected with HBV or coinfected with HBV and HIV-1 and have discontinued Tenofovir disoproxil fumarate (see Precautions).
Renal impairment, including cases of acute renal failure and Fanconi syndrome, has been reported. Tenofovir disoproxil fumarate should be avoided with concurrent or recent use of a nephrotoxic agent (e.g. high-dose or multiple NSAIDs) (see Precautions).
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported. Treatment with Tenofovir disoproxil fumarate should be suspended in any patient who develops clinical symptoms suggestive of lactic acidosis or pronounced hepatotoxicity (see Precautions).
Tenofovir disoproxil fumarate should not be co administered with DESCOVY, GENVOYA, STRIBILD, TRUVADA or tenofovir alafenamide (see Precautions).
Tenofovir disoproxil fumarate should not be administered in combination with HEPSERA (see Precautions).
Decreases in bone mineral density have been observed with the use of Tenofovir disoproxil fumarate Bone mineral density monitoring should be considered in patients who have a history of pathologic bone fracture or at risk for osteopenia (see Precautions).
In some patients treated with combination antiretroviral therapy, including Tenofovir disoproxil fumarate, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms. Advise patients to inform their healthcare provider immediately of any symptoms of infection (see Precautions).
In the treatment of chronic hepatitis B, the optimal duration of treatment is unknown. The relationship between response and long-term prevention of outcomes such as hepatocellular carcinoma is not known.